Human papillomavirus type 6 and 11 proteins (HPV-6/11 proteins)

Human papillomavirus (HPV) types 6 and 11 are non-enveloped, double-stranded DNA viruses categorized as low-risk genotypes because they are rarely associated with invasive malignancy. They are the primary causative agents for approximately 90% of anogenital warts (condyloma acuminata) and are the leading cause of recurrent respiratory papillomatosis (RRP), a condition characterized by benign growths in the airway (CDC, 2021). The viral genome encodes early proteins (E1, E2, E4, E5, E6, and E7) that manage viral replication and host cell cycle manipulation, and late proteins (L1 and L2) that form the structural capsid (UniProt, P03101). While the E6 and E7 proteins of these types have significantly lower oncogenic potential than those of high-risk types like HPV 16, they still drive the abnormal cellular proliferation seen in benign lesions. The L1 major capsid protein is the central target for prophylactic vaccines, which use virus-like particles to elicit a protective immune response before exposure (WHO, 2022). Current therapeutic strategies for existing infections focus on physical destruction of lesions or the use of immunomodulators to enhance the host's ability to clear the virus, as there are currently no widely approved drugs that directly inhibit HPV-6/11 viral protein function.

Other names

HPV6 proteinsHPV11 proteinsLow-risk human papillomavirus proteinsCondyloma acuminata virus proteinsHPV-6/11 L1 capsid proteins

Prophylactic vaccines utilize recombinant L1 major capsid proteins assembled into virus-like particles (VLPs) to induce high titers of neutralizing antibodies, which prevent the virus from entering host basal epithelial cells (StatPearls, 2023). Therapeutic agents like imiquimod act as toll-like receptor 7 (TLR7) agonists, stimulating the innate and adaptive immune systems to recognize and clear HPV-infected cells (PubMed, PMID: 15251341). Topical antimitotics such as podofilox induce necrosis of the infected tissue by arresting the cell cycle in metaphase (NIH, PubChem).